Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px
Document › Details

Kiadis Pharma N.V.. (10/18/18). "Press Release: Kiadis Pharma Launches a Private placement of approximately 3.7 Million New Shares [Not for United States, Australia, Canada, Japan, South Africa or any other jurisdiction where unlawful]". Amsterdam.

Organisations Organisation Kiadis Pharma N.V. (Euronext: KDS)
  Group Kiadis (Group)
  Organisation 2 Optimum Strategic Communications
Products Product ATIR101™ (Kiadis)
  Product 2 venture capital
Index term Index term Kiadis–SEVERAL: investment, 201810 private placment €31.2m with 3.9m new shares at €8/share
Persons Person Hård, Karl (Kiadis 201709–201812 Head IR + Communications LEFT 1/19 before Redx Pharma + AstraZeneca)
  Person 2 Clark, Mary (Optimum Strategic Communications 201710 before Hume Brophy + M:Communications + Capital MSL)

Record changed: 2023-06-05


Picture Berlin Partner Voices from HealthCapital Charpentier 650x200px

More documents for Kiadis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Special Topic HealthCapital Berlin-Brandenburg 650x300px

» top